NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-31
Reading BIIB? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 1% over the past year.
View GrowthManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 2% a day.
View RiskMostly healthy — no soft spokes
Biogen's growth in its Alzheimer's treatment portfolio must continue to justify its current valuation. Revenue grew 3% year over year, and the company beat earnings expectations by 356% in the latest quarter. It trades at 13× P/E, which is below the peer median of 20×, indicating that the price reflects less growth than forecasted. A specific risk is the potential for a credibility hit if Biogen were to cut guidance after recently raising it, which our model puts at a 12% miss probability. Peer multiples imply a price about 12% above where it trades. This read is provisional.
Trailing returns as of 2026-07-31. BIIB is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 38 analysts currently covering BIIB (as of Jul 2026).
Based on 14 Wall Street analysts offering 12-month price targets for BIIB in the last 4 months.
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Advances: Drive sustainable revenue growth with Growth Portfolio expansion
Positive outlook on portfolio expansion and pipeline readouts.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $202.95
The last 12 months of price, then the range of analyst 12-month targets from today’s $202.95.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Manage revenue decline
Positive EPS guidance supports revenue management objectives.
Advances: Manage revenue decline
Fresh Alzheimer's data supports revenue management efforts.
Threatens: Manage revenue decline
Negative data for Alzheimer's drug could hinder revenue management.
Advances: Investment for growth
Approval of LEQEMBI autoinjector supports growth investment.
Advances: Manage revenue decline
Positive trial results could reverse revenue decline.
New drug data could significantly impact revenue growth.
Advances: Investment for growth
Upgrade indicates confidence in growth potential and pipeline.
